FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

Table 2 Outcomes in the overall population and propensity score-matched population according to first-line chemotherapy, n (%)

Outcomes	Overall population			Propensity score-matched population
	FOLFIRINOX (n = 124)	FOLFOXIRI (n = 165)	P value	FOLFIRINOX (n = 96)	FOLFOXIRI (n = 96)	P value
Number of cycles, median [IQR]	11.0 [6.0-13.0]	7.0 [4.0-13.0]	0.027	11.0 [6.0-14.0]	7.0 [4.0-14.5]	0.164
Missing	1	0		1	0
RECIST best response			0.187			0.079
Complete or partial response	53 (47.8)	49 (37.1)		41 (47.7)	25 (32.5)
Stability	31 (27.9)	39 (29.6)		24 (27.9)	22 (28.5)
Progression	27 (24.3)	44 (33.3)		21 (24.4)	30 (39.0)
Missing	13	33		108	19
Toxicity of grade 3 or 4			0.079			0.148
No	95 (80.5)	117 (71.3)		72 (80.0)	68 (70.8)
Yes	23 (19.5)	47 (28.7)		18 (20.0)	28 (29.2)
Digestive	5 (4.2)	21 (12.8)		5 (5.6)	9 (9.4)
Hematology	1 (0.9)	5 (3.1)		1 (1.0)	4 (4.2)
Neurology	9 (7.6)	14 (8.5)		6 (6.7)	9 (9.4)
Other	8 (6.8)	7 (4.3)		6 (6.7)	6 (6.2)
Missing	6	1		6	0
Reason for discontinuation			0.291			0.441
Progression	83 (68.0)	108 (65.5)		63 (67.0)	67 (69.8)
Toxicity	12 (9.9)	10 (6.0)		12 (12.8)	7 (7.3)
Other	27 (22.1)	47 (28.5)		19 (20.2)	22 (22.9)
Missing	2	0		2	0
Maintenance			0.194			0.553
Yes	56 (45.2)	62 (37.6)		39 (40.6)	35 (36.5)
No	68 (54.8)	103 (64.4)		57 (59.4)	61 (63.5)
Second-line chemotherapy administration			0.643			0.636
Yes	91 (73.4)	117 (70.9)		69 (71.9)	66 (68.8)
No	33 (26.6)	48 (29.1)		27 (28.1)	30 (31.2)

χ² tests or Fisher’s exact tests were used to compare proportions, and Wilcoxon tests were used to compare continuous variables between the FOLFIRINOX and FOLFOXIRI groups. All statistical tests were two-sided. IQR: Interquartile range.